肠道殖民丝虫像益生菌复合材料用于多交叉综合协同治疗炎症性肠病的综合协同治疗
Ya Wang1, Yujie Zhang2, Pengqian Wang3
1Center for Gut Microbiome Research, Med-X Institute, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, P. R. China.
Small (Weinheim an der Bergstrasse, Germany)
|February 9, 2024
概括
新的丝虫状益生菌复合物 (SCPC) 为炎症性肠病 (IBD) 提供了先进的治疗方法. 这些受保护的益生菌显示出优越的肠道殖民,并有效地减少IBD治疗的炎症和氧化应激.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 微生物学 微生物学
背景情况:
- 炎症性肠病 (IBD) 提出了复杂的挑战,包括肠道屏障破坏,炎症,氧化应激和失生症.
- 目前用于IBD的益生菌疗法面临由于恶劣的胃肠道环境和缺乏殖民性的限制.
研究的目的:
- 开发和评估类似于丝虫的益生菌复合物 (SCPCs),用于增强炎性肠病 (IBD) 治疗.
- 为了改善益生菌的生存,肠道殖民化和IBD环境中的治疗疗效.
主要方法:
- 益生菌被封装使用顺序分层的丝素 (SS),酸 (TA) 和多多巴胺来形成SCPCs.
- 在体外和体外模型被用来评估SCPC对胃肠道环境的耐药性,肠道殖民以及对IBD特征的治疗效果.
主要成果:
- 与未涂层益生菌相比,SCPCs表现出超过200倍的肠道殖民.
- SCPCs显著降低了肠道透性 (9.7倍),IL-6 (8.9倍) 和TNF-α (2.9倍) 的水平.
- SCPCs实现了92.25%的活性氧物种清除率,改善了有益细菌,并减少了致病细菌.
结论:
- SCPCs为益生菌输送提供了一个强大的平台,克服了炎症性肠病 (IBD) 常规疗法的局限性.
- 复合结构保护益生菌,并与它们协同作用,全面解决IBD病理,包括屏障功能障碍,炎症,氧化应激和微生物群失衡.
更多相关视频
相关概念视频
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
01:21Drugs for Treatment of Constipation-Predominant IBS
164
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
164
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:21Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
01:29Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141